<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="56288">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02373371</url>
  </required_header>
  <id_info>
    <org_study_id>I14034</org_study_id>
    <nct_id>NCT02373371</nct_id>
  </id_info>
  <brief_title>Actinic Keratoses Treatment With Metvix® in Combination With Light</brief_title>
  <official_title>Efficacy and Safety of Metvix® Natural Daylight Photodynamic Therapy Versus Conventional Metvix® Photodynamic Therapy in Subject With Mild Actinic Keratoses</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Limoges</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Galderma</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Limoges</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective of this study is to compare efficacy and safety of Metvix® natural
      daylight photodynamic therapy with those of Metvix® conventional photodynamic therapy in
      subjects with mild actinic keratoses (intra-individual comparison)
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2015</start_date>
  <completion_date type="Anticipated">December 2016</completion_date>
  <primary_completion_date type="Anticipated">October 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent change from baseline in total number of treated mild lesions per side at week 12</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>Percent change from baseline in total number of treated mild lesions per side at week 12</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">26</enrollment>
  <condition>Actinic Keratoses</condition>
  <arm_group>
    <arm_group_label>Daylight</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Metvix® (160mg/g) and Photodynamic Therapy Daylight One session at baseline</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Conventional treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Metvix® (160mg/g) and Photodynamic Therapy Blue light One session at baseline</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metvix®</intervention_name>
    <arm_group_label>Daylight</arm_group_label>
    <arm_group_label>Conventional treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Photodynamic Therapy Blue light</intervention_name>
    <description>Photodynamic therapy (PDT) is a medical treatment that utilizes a photosensitizing molecule (Metvix) and a blue light source to activate the applied drug</description>
    <arm_group_label>Conventional treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Photodynamic Therapy Daylight</intervention_name>
    <description>Photodynamic therapy (PDT) is a medical treatment that utilizes a photosensitizing molecule (Metvix) and a the day light to activate the applied drug</description>
    <arm_group_label>Daylight</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female above 18 years;

          -  Subject with clinical diagnosis of mild Actinic Keratosis (AK) on the face or the
             scalp with or without clinical diagnosis of moderate AK on the target areas (TAs);

        Exclusion Criteria:

          -  Subject with clinical diagnosis of at least one severe AK on TAs

          -  Subject with clinical diagnosis of other skin disease (including non-melanoma skin
             cancer) on the TAs;

          -  Subject with pigmented AK on the TAs
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Christophe BEDANE, MD</last_name>
    <phone>0555056430</phone>
    <email>christophe.bedane@chu-limoges.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>safe ASSIKAR, MD</last_name>
    <phone>0555056430</phone>
    <email>as.safae@hotmail.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Limoges University Hospital</name>
      <address>
        <city>Limoges</city>
        <zip>87042</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christophe BEDANE, MD</last_name>
      <phone>0555056430</phone>
      <email>christophe.bedane@chu-limoges.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2015</verification_date>
  <lastchanged_date>August 31, 2015</lastchanged_date>
  <firstreceived_date>February 16, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Keratosis</mesh_term>
    <mesh_term>Keratosis, Actinic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Methyl 5-aminolevulinate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
